Ursprung des Netzwerks ersten Grades von Bai Shun Yan
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Cheng Xin Venture Capital Group
 Cheng Xin Venture Capital Group Investment ManagersFinance Cheng Xin Venture Capital Group (CXVCG) is a venture capital investment firm located in Taipei, Taiwan. Established in 1990, the firm manages a number of investment funds focusing on high technology and biotechnology firms.
7
| Private Company | Investment Managers | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Bai Shun Yan
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| TAIWAN GLASS IND. CORP. | Industrial Specialties | Director/Board Member | |
| CAPITAL SECURITIES CORPORATION | Investment Banks/Brokers | Director/Board Member | |
| THE AMBASSADOR HOTEL,LTD. | Hotels/Resorts/Cruise lines | Director/Board Member | |
| Po-Chi Investment Co. Ltd. | Chairman | ||
| University of Wisconsin | College/University | Doctorate Degree | |
| EMPOWER TECHNOLOGY CORPORATION. | Telecommunications Equipment | Director/Board Member | |
| Tsinghua University | College/University | Undergraduate Degree | |
| Hong Kong Baptist University | College/University | Undergraduate Degree | |
| LOTUS PHARMACEUTICAL CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
| MYCENAX BIOTECH INC. | Biotechnology | Director/Board Member | |
| FEATURE INTEGRATION TECHNOLOGY INC. | Semiconductors | Director/Board Member | |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Biotechnology | Director/Board Member | |
| TWI PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| TWI BIOTECHNOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
| MEDEON BIODESIGN, INC. | Electronic Equipment/Instruments | Director/Board Member | |
| EIRGENIX INC. | Biotechnology | Director/Board Member | |
| ASLAN PHARMACEUTICALS LIMITED | Biotechnology | Director/Board Member | |
Allgenesis Biotherapeutics, Inc.
 Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Biotechnology | Founder | |
| Noratech Pharmaceuticals, Inc. | Director/Board Member | ||
| Taiwania Capital Management Corp. | Investment Managers | Private Equity Investor |
Statistik
International
| Taiwan | 18 |
| Singapur | 3 |
| Vereinigte Staaten | 2 |
| China | 2 |
| Hong Kong | 2 |
Sektoral
| Health Technology | 10 |
| Consumer Services | 5 |
| Electronic Technology | 4 |
| Finance | 3 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 17 |
| Private Equity Investor | 7 |
| Chairman | 2 |
| President | 2 |
| Undergraduate Degree | 2 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Chih Lung Shen | 15 |
| Han Tung Lim | 8 |
| Michael Huang | 2 |
| Felix Lu | 1 |
| Margaret Kuo | 1 |
| Bai Ling Yan | 1 |
| Ri Xi Lai | 1 |
- Börse
- Insiders
- Bai Shun Yan
- Unternehmensverbindungen
